Clinical Trial Update: Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study [Phase 2]

View source ↗

Summary

A prospective Phase II, single-arm trial evaluating tislelizumab in combination with anlotinib and nab-paclitaxel in III resectable non-small cell lung cancer. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abraxane (nab-paclitaxel) (nab-paclitaxel)
• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: NSCLC, Tislelizumab | Phase 2 | Status: NOT_YET_RECRUITING